US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
pharma
Amdipharm Mercury (Australia)
Amdipharm Mercury (Australia) Pty Limited
Amdipharm Mercury (Australia) drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
AU HQ
TGA registrant Type
Company details
- Status
- Public
- HQ
- AU
- Programs
- 0
- Drugs
- 11
- Patents
- 0
Amdipharm Mercury (Australia) pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Amdipharm Mercury (Australia) drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Amdipharm Mercury (Australia) in public FDA and regional records. Molecular target: Thyroid peroxidase.
- Target
- Thyroid peroxidase
- Mechanism
- Thyroid peroxidase inhibitor
-
Development asset linked to Amdipharm Mercury (Australia) in public FDA and regional records. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Amdipharm Mercury (Australia) in public FDA and regional records.
-
Development asset linked to Amdipharm Mercury (Australia) in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
Development asset linked to Amdipharm Mercury (Australia) in public FDA and regional records. Mechanism: Somatostatin receptor 2 agonist.
- Mechanism
- Somatostatin receptor 2 agonist
-
obeticholic acid
Alimentary tract and metabolism (A05)US regulatory status: approved. Molecular target: Bile acid receptor.
- Target
- Bile acid receptor
- Mechanism
- Bile acid receptor FXR agonist
-
Development asset linked to Amdipharm Mercury (Australia) in public FDA and regional records. Mechanism: Adrenergic receptor alpha antagonist.
- Mechanism
- Adrenergic receptor alpha antagonist
-
Development asset linked to Amdipharm Mercury (Australia) in public FDA and regional records. Mechanism: Monoamine oxidase inhibitor.
- Mechanism
- Monoamine oxidase inhibitor
-
zonisamide
Nervous system (N03)US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker